Drugs / MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells
MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02584829 | Nov 2015 → Dec 2018 | — | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT01758458 | Feb 2013 → May 2016 | cutaneous neuroendocrine carcinoma | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02584829 ↗ |
| Action | Deplete | “Infusing these cells back into the patient may help the body build an effective immune response to kill Merkel cell carcinoma.” NCT02584829 ↗ |
| Modality | Cell therapy | “MCPyV TAg-specific polyclonal autologous CD8+ T cells” NCT01758458 ↗ |
| Route | Intravenous | “Given IV” NCT01758458 ↗ |